The Role of Minimally Invasive Surgery in Pancreatic Cancer

FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jaffer A. Ajani, MD, discussed the trials investigating the use of immune checkpoint inhibitors in patients with upper gastrointestinal cancers.

In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.

A phase 1 study is investigating anti-TIGIT therapy combined with immune checkpoint inhibition for the patients with metastatic microsatellite stable colorectal cancer.

Patrick Wagner, MD, director of complex general surgical oncology at AHN Cancer Institute, discussed the current state of important developments in treatment of gallbladder cancer.